• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

相似文献

1
New Targeted Therapies and Combinations of Treatments for Cervical, Endometrial, and Ovarian Cancers: A Year in Review.新的靶向治疗和治疗宫颈癌、子宫内膜癌和卵巢癌的联合治疗方案：年度回顾。
Curr Oncol. 2022 Apr 17;29(4):2835-2847. doi: 10.3390/curroncol29040231.
2
Annual Report of the Committee on Gynecologic Oncology, Japan Society of Obstetrics and Gynecology: Patient Annual Report for 2014 and Treatment Annual Report for 2009.日本妇产科学会妇科肿瘤委员会年度报告：2014年患者年度报告及2009年治疗年度报告。
J Obstet Gynaecol Res. 2017 Nov;43(11):1667-1677. doi: 10.1111/jog.13450. Epub 2017 Sep 11.
3
Annual report of the committee on gynecologic oncology, the Japan Society of Obstetrics and Gynecology: Annual patients report for 2015 and annual treatment report for 2010.日本妇产科学会妇科肿瘤委员会年度报告：2015年年度患者报告及2010年年度治疗报告
J Obstet Gynaecol Res. 2019 Feb;45(2):289-298. doi: 10.1111/jog.13863. Epub 2018 Nov 13.
4
Annual report of the committee on gynecologic oncology, the Japan Society of Obstetrics and Gynecology: Annual patient report for 2019 and annual treatment report for 2014.日本妇产科协会妇科肿瘤学委员会年度报告：2019 年年度患者报告和 2014 年年度治疗报告。
J Obstet Gynaecol Res. 2022 Jul;48(7):1570-1579. doi: 10.1111/jog.15284. Epub 2022 May 27.
5
Annual report of the Committee on Gynecologic Oncology, the Japan Society of Obstetrics and Gynecology: Annual Patient Report for 2020 and Annual Treatment Report for 2015.日本妇产科学会妇科肿瘤学委员会年度报告：2020年年度患者报告及2015年年度治疗报告
J Obstet Gynaecol Res. 2023 Nov;49(11):2584-2592. doi: 10.1111/jog.15767. Epub 2023 Aug 21.
6
Annual report of the Committee on Gynecologic Oncology, the Japan Society of Obstetrics and Gynecology: Annual patient report for 2017 and annual treatment report for 2012.日本妇产科学会妇科肿瘤学委员会年度报告：2017年年度患者报告及2012年年度治疗报告
J Obstet Gynaecol Res. 2021 May;47(5):1631-1642. doi: 10.1111/jog.14724. Epub 2021 Feb 25.
7
Annual report of the Committee on Gynecologic Oncology, the Japan Society of Obstetrics and Gynecology: Annual Patient Report for 2018 and Annual Treatment Report for 2013.日本妇产科协会妇科肿瘤学委员会年度报告：2018 年年度患者报告和 2013 年年度治疗报告。
J Obstet Gynaecol Res. 2022 Mar;48(3):541-552. doi: 10.1111/jog.15134. Epub 2022 Jan 13.
8
Annual report of the Committee on Gynecologic Oncology, the Japan Society of Obstetrics and Gynecology.日本妇产科学会妇科肿瘤学委员会年度报告
J Obstet Gynaecol Res. 2015 Feb;41(2):167-77. doi: 10.1111/jog.12596. Epub 2014 Nov 5.
9
New horizons for platinum-resistant ovarian cancer: insights from the 2023 American Society of Clinical Oncology (ASCO) and European Society for Medical Oncology (ESMO) Annual Meetings.铂耐药性卵巢癌的新视野：2023 年美国临床肿瘤学会（ASCO）和欧洲肿瘤内科学会（ESMO）年会的见解。
Int J Gynecol Cancer. 2024 May 6;34(5):760-772. doi: 10.1136/ijgc-2023-004927.
10
Change in practice in gynecologic oncology during the COVID-19 pandemic: a social media survey.2019年冠状病毒病大流行期间妇科肿瘤学的实践变化：一项社交媒体调查
Int J Gynecol Cancer. 2020 Aug;30(8):1101-1107. doi: 10.1136/ijgc-2020-001585. Epub 2020 Jun 7.

引用本文的文献

1
Genome Editing in Gynecological Oncology: The Emerging Role of CRISPR/Cas9 in Precision Cancer Therapy.妇科肿瘤学中的基因组编辑：CRISPR/Cas9在精准癌症治疗中的新兴作用
Ther Innov Regul Sci. 2025 May 20. doi: 10.1007/s43441-025-00807-w.
2
Shared decision-making in patients with gynecological cancer and healthcare professionals: a cross-sectional observational study in Japan.妇科癌症患者与医疗保健专业人员之间的共同决策：日本的一项横断面观察研究。
J Gynecol Oncol. 2025 May;36(3):e47. doi: 10.3802/jgo.2025.36.e47. Epub 2024 Nov 19.
3
Triage performance of PAX1/JAM3 in opportunistic cervical cancer screening of non‒16/18 human papillomavirus-positive women: a multicenter prospective study in China.PAX1/JAM3 在非 16/18 型人乳头瘤病毒阳性妇女机会性宫颈癌筛查中的诊断效能：中国多中心前瞻性研究。
Clin Epigenetics. 2024 Aug 16;16(1):108. doi: 10.1186/s13148-024-01731-w.
4
SIM2: Its Prognostic Significance and Oncogenic Role in Endometrial Carcinoma.SIM2：其在子宫内膜癌中的预后意义及致癌作用
Onco Targets Ther. 2024 Jan 26;17:45-61. doi: 10.2147/OTT.S440788. eCollection 2024.
5
A prognostic model for ovarian neoplasms established by an integrated analysis of 1580 transcriptomic profiles.基于 1580 个转录组谱的综合分析建立的卵巢肿瘤预后模型。
Sci Rep. 2023 Nov 8;13(1):19429. doi: 10.1038/s41598-023-45410-x.
6
Inhibition of CDK1 by RO-3306 Exhibits Anti-Tumorigenic Effects in Ovarian Cancer Cells and a Transgenic Mouse Model of Ovarian Cancer.RO-3306 通过抑制 CDK1 在卵巢癌细胞和卵巢癌转基因小鼠模型中表现出抗肿瘤作用。
Int J Mol Sci. 2023 Aug 3;24(15):12375. doi: 10.3390/ijms241512375.
7
Identification of Gαi3 as a novel molecular therapeutic target of cervical cancer.鉴定 Gαi3 为宫颈癌的新型分子治疗靶点。
Int J Biol Sci. 2022 Sep 6;18(15):5667-5680. doi: 10.7150/ijbs.77126. eCollection 2022.

本文引用的文献

1
BYL719 (alpelisib) for the treatment of PIK3CA-mutated, recurrent/advanced cervical cancer.BYL719（阿培利司）用于治疗PIK3CA突变的复发/晚期宫颈癌。
Tumori. 2023 Apr;109(2):244-248. doi: 10.1177/03008916211073621. Epub 2022 Mar 20.
2
Late Toxicity After Adjuvant Conventional Radiation Versus Image-Guided Intensity-Modulated Radiotherapy for Cervical Cancer (PARCER): A Randomized Controlled Trial.辅助常规放疗与图像引导调强放疗治疗宫颈癌（PARCER）的晚期毒性：一项随机对照试验。
J Clin Oncol. 2021 Nov 20;39(33):3682-3692. doi: 10.1200/JCO.20.02530. Epub 2021 Sep 10.
3
Chemotherapy with or without avelumab followed by avelumab maintenance versus chemotherapy alone in patients with previously untreated epithelial ovarian cancer (JAVELIN Ovarian 100): an open-label, randomised, phase 3 trial.阿维鲁单抗联合或不联合化疗序贯阿维鲁单抗维持治疗与单纯化疗用于未经治疗的上皮性卵巢癌患者（JAVELIN Ovarian 100）：一项开放标签、随机、III 期临床试验。
Lancet Oncol. 2021 Sep;22(9):1275-1289. doi: 10.1016/S1470-2045(21)00342-9. Epub 2021 Aug 4.
4
COVID-19 impact on screening test volume through the National Breast and Cervical Cancer early detection program, January-June 2020, in the United States.2020 年 1 月至 6 月，美国全国乳腺癌和宫颈癌早期检测计划（NBCCEDP）中 COVID-19 对筛查检测量的影响。
Prev Med. 2021 Oct;151:106559. doi: 10.1016/j.ypmed.2021.106559. Epub 2021 Jun 30.
5
Assessment of Adult Women With Ovarian Masses and Treatment of Epithelial Ovarian Cancer: ASCO Resource-Stratified Guideline.成年女性卵巢肿块评估与上皮性卵巢癌治疗：ASCO 资源分层指南。
JCO Glob Oncol. 2021 Jun;7:1032-1066. doi: 10.1200/GO.21.00085.
6
Avelumab alone or in combination with chemotherapy versus chemotherapy alone in platinum-resistant or platinum-refractory ovarian cancer (JAVELIN Ovarian 200): an open-label, three-arm, randomised, phase 3 study.阿维鲁单抗单药或联合化疗对比单纯化疗用于铂耐药或铂难治性卵巢癌（JAVELIN Ovarian 200）：一项开放标签、三臂、随机、3期研究。
Lancet Oncol. 2021 Jul;22(7):1034-1046. doi: 10.1016/S1470-2045(21)00216-3. Epub 2021 Jun 15.
7
Effect of a Randomized, Controlled Trial on Surgery for Cervical Cancer.一项关于宫颈癌手术的随机对照试验的效果
N Engl J Med. 2021 Apr 29;384(17):1669-1671. doi: 10.1056/NEJMc2035819.
8
Atezolizumab, Bevacizumab, and Chemotherapy for Newly Diagnosed Stage III or IV Ovarian Cancer: Placebo-Controlled Randomized Phase III Trial (IMagyn050/GOG 3015/ENGOT-OV39).阿替利珠单抗、贝伐珠单抗联合化疗治疗新诊断的 III 期或 IV 期卵巢癌：安慰剂对照随机 III 期试验（IMagyn050/GOG 3015/ENGOT-OV39）。
J Clin Oncol. 2021 Jun 10;39(17):1842-1855. doi: 10.1200/JCO.21.00306. Epub 2021 Apr 23.
9
Efficacy and safety of tisotumab vedotin in previously treated recurrent or metastatic cervical cancer (innovaTV 204/GOG-3023/ENGOT-cx6): a multicentre, open-label, single-arm, phase 2 study.替妥珠单抗Vedotin 在既往治疗的复发或转移性宫颈癌中的疗效和安全性（innovaTV 204/GOG-3023/ENGOT-cx6）：一项多中心、开放标签、单臂、2 期研究。
Lancet Oncol. 2021 May;22(5):609-619. doi: 10.1016/S1470-2045(21)00056-5. Epub 2021 Apr 9.
10
Genetic variation in cervical preinvasive and invasive disease: a genome-wide association study.宫颈前病变和浸润性疾病的遗传变异：全基因组关联研究。
Lancet Oncol. 2021 Apr;22(4):548-557. doi: 10.1016/S1470-2045(21)00028-0.

新的靶向治疗和治疗宫颈癌、子宫内膜癌和卵巢癌的联合治疗方案：年度回顾。

New Targeted Therapies and Combinations of Treatments for Cervical, Endometrial, and Ovarian Cancers: A Year in Review.

机构信息

Department of Oncology, "Carol Davila" University of Medicine and Pharmacy, 020021 Bucharest, Romania.

Department of Medical Oncology, University of Medicine and Pharmacy Craiova, 200349 Craiova, Romania.

出版信息

Curr Oncol. 2022 Apr 17;29(4):2835-2847. doi: 10.3390/curroncol29040231.

DOI:10.3390/curroncol29040231
PMID:35448205
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC9027198/
Abstract

This review of the meaningful data from 2021 on cervical, endometrial, and ovarian cancers aims to provide an update of the most clinically relevant studies presented at important oncologic congresses during the year (the American Society of Clinical Oncology (ASCO) Annual Meeting, the European Society for Medical Oncology (ESMO) Congress and the Society of Gynecologic Oncology (SGO) Annual Meeting). Despite the underlying existence of the COVID-19 pandemic, the last year has been notable in terms of research, with significant and promising advances in gynecological malignancies. Several major studies reporting the effects of innovative therapies for patients with cervical, endometrial, and ovarian cancers might change the medical practice in the future.

摘要

这篇综述回顾了 2021 年关于宫颈癌、子宫内膜癌和卵巢癌的有意义数据，旨在提供在当年重要肿瘤学会议（美国临床肿瘤学会（ASCO）年会、欧洲肿瘤内科学会（ESMO）大会和妇科肿瘤学会（SGO）年会）上展示的最具临床相关性的研究的最新信息。尽管存在 COVID-19 大流行，但过去一年在妇科恶性肿瘤的研究方面取得了显著而有前景的进展。一些重要的研究报告了创新疗法对宫颈癌、子宫内膜癌和卵巢癌患者的影响，这些研究可能会改变未来的医疗实践。